Medicago's H5N1 VLP Vaccine Found Effective Against Avian Flu
Posted on: Thursday, 20 March 2008, 06:00 CDT
Medicago has announced that its H5N1 avian influenza VLP vaccine, made from the Indonesian strain, has provided 100% protection in mice against a lethal challenge with live H5N1 viruses of the Vietnam strain.
In this study, mice were vaccinated with a range of doses of the company's VLP vaccine made from an Indonesian strain of H5N1 avian influenza. During the experiment, 100% of the vaccinated mice survived, while 100% of the control group died. The mice were challenged 80 days after vaccination with a live H5N1 strain from Vietnam. Results showed that mice vaccinated with Medicago's H5N1 VLP vaccine were fully protected from illness and subsequent death even at the low dose of 0.5 microgram.
Including these results, the company has now established that its lead H5N1 VLP vaccine has the potential to protect against three strains of pandemic influenza. In earlier studies, the company demonstrated that its vaccine provides 100% cross-protection in mice against an influenza strain from Turkey.
Nathalie Landry, Medicago's vice president of product development, said: "We believe these results significantly enhance the value of our H5N1 VLP vaccine. We expect to initiate studies in ferrets in the coming weeks and look forward to taking this new vaccine candidate into clinical trials in early 2009."
Source: Datamonitor
Related Articles
- Sanofi Pasteur to Donate 60 Million Doses of H5N1 Vaccine to WHO Over 3 Years for Its Influenza Vaccine Global Stockpile
- Sinovac Commences Vaccination on Volunteers for Phase II Clinical Trial on Pandemic Influenza H5N1 Vaccine
- GlaxoSmithKline: Dose-Sparing H5N1 Vaccine Application Filed in Europe
- CYNTEGRA Releases VIOGENIX DUO, the World's First Combined Diagnostic Test for Cats and Dogs That Detects Both the Avian H5N1 and Canine H3N8 Strains of Influenza A
- Hungary to Produce H5N1 Vaccine for Humans: PM
- Vietnam to Produce Human-Use H5N1 Vaccines Late This Year
- Vietnam Produces Human-Use H5N1 Vaccines on Lab Scale
- Sanofi Pasteur Delivers More H5N1 Vaccine for U.S. Government Pandemic Initiatives
- Sinovac Biotech Ltd. Begins Pandemic Flu (H5N1) Vaccine Clinical Trials
- France's Sanofi-Aventis to Produce H5N1 Vaccine
User Comments (0)

RSS Feeds